Symptoms of weight loss injections: separating normal from serious

The biggest misconception: side effects are unavoidable and severe

The most widespread worry our prescribers hear is that weight loss injections make people violently ill for months. The data tells a more measured story. In the SURMOUNT-1 trial of tirzepatide, gastrointestinal events were common (nausea affected roughly 30–45% of participants depending on dose) but the great majority were rated mild or moderate, and discontinuation due to side effects was relatively low for a medicine producing over 20% average body-weight reduction at the highest dose. Semaglutide's STEP programme showed a similar picture.

What actually happens for most people is a week or two of unsettled digestion after starting or stepping up. Nausea tends to be the lead symptom, often accompanied by a reduced appetite (which is part of the medicine's mechanism, not a complication), and sometimes belching or reflux. Constipation and diarrhoea can alternate in the early weeks. Fatigue and mild headaches crop up too. These are documented in the NHS patient information for tirzepatide and the equivalent semaglutide page, both of which are worth reading alongside the Patient Information Leaflet supplied with your pen.

The dose-escalation schedule (starting low and stepping up gradually over weeks) exists precisely to reduce the severity of these symptoms. It is not an optional slow lane; it is the mechanism that makes the treatment tolerable for most people.

Symptoms that need a GP call or emergency care, not a wait-and-see

A small number of symptoms are red flags. Pancreatitis is a known but uncommon risk: in January 2026 the MHRA issued a Drug Safety Update specifically highlighting acute pancreatitis, urging patients on GLP-1 medicines to seek urgent help for severe, persistent stomach pain that spreads to the back, with or without vomiting. That kind of pain is different from ordinary nausea and should not be managed at home.

Other symptoms that need prompt attention include signs of a serious allergic reaction (swelling of the face, lips or throat, difficulty breathing), gallbladder-related pain (sharp upper-right abdominal pain, especially after eating), and persistent vomiting or diarrhoea severe enough to cause dehydration. If you are also being treated for type 2 diabetes with insulin or a sulphonylurea, low blood sugar is an additional consideration worth discussing with your prescriber. Any concerns about the downsides of weight loss injections are worth raising before you start, not after.

Suspected side effects (including ones you are unsure about) can be reported via the MHRA Yellow Card scheme. You do not need a confirmed diagnosis to file a report; that is the point of the scheme.

Injection-site symptoms and the practicalities of injecting

Both Mounjaro and Wegovy are given as once-weekly subcutaneous injections into the abdomen, thigh or upper arm. Redness, mild itching or a small lump at the injection site are common, particularly if the same spot is used repeatedly. Rotating the site each week, and leaving at least a few centimetres between injection points, reduces this. Cleaning the skin beforehand is straightforward, alcohol swabs are an inexpensive practical addition if you want them.

The pen itself is pre-filled and pre-set; there is no drawing up or measuring involved. If you order through our pharmacy, it arrives via DPD the next working day in plain, unbranded packaging, and tracking is sent to your phone so you know when to expect it. Both pens need to be kept refrigerated until use. The exact room-temperature window once removed is stated in the Patient Information Leaflet, that is the figure to follow, not a number from a webpage.

Good injection technique is not complicated but it is worth doing properly. If you have questions about it after starting treatment, our prescribers are available for aftercare seven days a week. Details of our clinical team are on the prescriber profile page.

Who should raise concerns before starting, and who shouldn't self-select out

Some medical histories warrant particular care. A personal or family history of medullary thyroid carcinoma or MEN2, a past episode of pancreatitis, or serious gastroparesis are among the factors a prescriber will specifically ask about. These are not questions for a checklist you skim, they are the reason the clinical consultation exists.

Equally, some people rule themselves out prematurely because of a bad experience with a different medicine, or because a friend had significant side effects. The two medicines have overlapping but not identical profiles (tirzepatide acts on both the GIP and GLP-1 pathways, semaglutide on GLP-1 alone) and individual responses vary considerably. If you are researching your options, our guide to weight loss injections covers the full range of treatments available, and reading about what to expect from a weight loss injection regimen can help set realistic expectations before you commit. For those specifically weighing up Mounjaro, the detail on using Mounjaro as a weight loss injection is worth reviewing alongside the broader clinical picture. If you want to understand your options properly, finding out how to get weight loss injections through a regulated service means a prescriber reviews your medical history and answers questions specific to you, rather than you navigating probability percentages from trial data.

Women using oral contraceptives and starting tirzepatide should add a non-oral method of contraception for the first four weeks of treatment and for four weeks after each dose increase, as absorption of the pill may be reduced, a specific detail covered in NHS England's guidance on weight management injections and worth discussing with your prescriber. Pregnancy and breastfeeding are contraindications; these medicines are not licensed for under-18s.